Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actimab-A + CLAG-M
- Development stage
- Unknown
- Lead developer
- Actinium Pharmaceuticals
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Actimab-A + CLAG-M is a combination therapeutic regimen developed by Actinium Pharmaceuticals for the treatment of relapsed or refractory acute myeloid leukemia (AML). Actimab-A is an antibody radio-conjugate (ARC) consisting of the anti-CD33 monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium-225 (Ac-225). CLAG-M is a salvage chemotherapy regimen comprising cladribine, cytarabine (Ara-C), filgrastim (G-CSF), and mitoxantrone. The scientific rationale for the combination is that CLAG-M provides rapid debulking of leukemia cells, while Actimab-A delivers precision CD33-targeted alpha-particle radiation to eliminate residual disease via double-strand DNA breaks. This regimen is particularly targeted at high-risk patients, including those with TP53 mutations, prior venetoclax therapy, or prior allogeneic stem cell transplant, and has demonstrated high rates of MRD-negativity in clinical trials.
- Other names
- lintuzumab-Ac225 + CLAG-M
02
Targets
CD33 (Myeloid cell surface antigen CD33)RNR (Ribonucleotide reductase)DNA polymerase familyTOP2A (DNA topoisomerase II)DNACSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on Actimab-A + CLAG-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actimab-A + CLAG-M.